Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2010, Article ID 906163, 4 pages
http://dx.doi.org/10.1155/2010/906163
Clinical Study

Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism

Department of Endocrinology, St. Bartholomew's Hospital, London EC1A 7BE, UK

Received 29 December 2009; Accepted 8 March 2010

Academic Editor: Aaron I. Vinik

Copyright © 2010 V. J. Moyes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. L. Brandi, R. F. Gagel, A. Angeli et al., “Consensus: guidelines for diagnosis and therapy of MEN type 1 and type 2,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 12, pp. 5658–5671, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. J. R. Burgess, R. David, T. M. Greenaway, V. Parameswaran, and J. J. Shepherd, “Osteoporosis in multiple endocrine neoplasia type 1. Severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomy,” Archives of Surgery, vol. 134, no. 10, pp. 1119–1123, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Marx, “Multiple endocrine neoplasia type 1,” in The Metabolic and Molecular Bases of Inherited Disease, C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, Eds., McGraw-Hill, New York, NY, USA, 8th edition, 2001. View at Google Scholar
  4. S. M. Moe, J. Cunningham, J. Bommer et al., “Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl,” Nephrology Dialysis Transplantation, vol. 20, no. 10, pp. 2186–2193, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. S. J. Silverberg, M. R. Rubin, C. Faiman et al., “Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 10, pp. 3803–3808, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. M. Peacock, J. P. Bilezikian, P. S. Klassen, M. D. Guo, S. A. Turner, and D. Shoback, “Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 1, pp. 135–141, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. D. M. Shoback, J. P. Bilezikian, S. A. Turner, L. C. McCary, M. D. Guo, and M. Peacock, “The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 12, pp. 5644–5649, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. J. P. Bilezikian, J. T. Potts Jr., G. E.-H. Fuleihan et al., “Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 12, pp. 5353–5361, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Rossini, D. Gatti, G. Isaia, L. Sartori, V. Braga, and S. Adami, “Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism,” Journal of Bone and Mineral Research, vol. 16, no. 1, pp. 113–119, 2001. View at Google Scholar · View at Scopus
  10. A. Faggiano, L. B. Tavares, L. Tauchmanova et al., “Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients,” Clinical Endocrinology, vol. 69, no. 5, pp. 756–762, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. I. Lancranjan and A. B. Atkinson, “Results of a European multicentre study with Sandostatin LAR in acromegalic patients,” Pituitary, vol. 1, no. 2, pp. 105–114, 1999. View at Google Scholar · View at Scopus
  12. B. Lembcke, W. Creutzfeldt, S. Schleser, R. Ebert, C. Shaw, and I. Koop, “Effect of the somatostatin analogue Sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men,” Digestion, vol. 36, no. 2, pp. 108–124, 1987. View at Google Scholar · View at Scopus
  13. A. Moschetta, M. F. J. Stolk, J. F. Rehfeld et al., “Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR,” Alimentary Pharmacology and Therapeutics, vol. 15, no. 2, pp. 181–185, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Falchetti, A. Cilotti, L. Vagelli et al., “A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet,” Nature Clinical Practice Endocrinology and Metabolism, vol. 4, no. 6, pp. 351–357, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus